What's new at the pCPA
See all newsThe pCPA’s 2025–26 impact report now available
The pCPA is pleased to share its 2025–26 impact report, Ready for the Road Ahead.
The pCPA helped public drug plans save over $5 billion
The pCPA reached new heights when it comes to savings for public drug plans in 2025–26.
Help shape the expansion of the early negotiation process!
We’re exploring ways to expand the early negotiation process (ENP), and we want to hear from you.
What we've accomplished
$4.4B
Estimated savings for brand-name drugs in 2025–26
$940M
Estimated savings for generic drugs in 2025–26
809
negotiations ended with agreements since 2010
Performance dashboard
Explore the latest negotiation outcomes, timelines, and savings for public drug plans in Canada
Get to know us
We negotiate drug prices with manufacturers on behalf of federal, provincial, and territorial public drug plans to support sustainable coverage and better health outcomes in Canada.
Get to know our processes
We’ve developed different pathways for specific drugs, to support timely negotiations. Explore the pages linked below to learn how our pathways work, get crucial process insights, and access forms and other resources for manufacturers.
Brand-name drugs
Learn how the pCPA negotiates prices for brand‑name drugs, and access relevant forms, guidelines, and resources available to manufacturers.
Generic drugs
Find out how the pCPA negotiates prices for generic drugs, and access forms, tools, and guidance resources designed for manufacturers.
Biosimilar drugs
See how the pCPA approaches price negotiations for biosimilar drugs, and consult manufacturer‑specific forms and supporting resources.